» Articles » PMID: 21669570

Iron Overload and HFE Gene Mutations in Polish Patients with Liver Cirrhosis

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2011 Jun 15
PMID 21669570
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increased liver iron stores may contribute to the progression of liver injury and fibrosis, and are associated with a higher risk of hepatocellular carcinoma development. Pre-transplant symptoms of iron overload in patients with liver cirrhosis are associated with higher risk of infectious and malignant complications in liver transplant recipients. HFE gene mutations may be involved in the pathogenesis of liver iron overload and influence the progression of chronic liver diseases of different origins. This study was designed to determine the prevalence of iron overload in relation to HFE gene mutations among Polish patients with liver cirrhosis.

Methods: Sixty-one patients with liver cirrhosis included in the study were compared with a control group of 42 consecutive patients subjected to liver biopsy because of chronic liver diseases. Liver function tests and serum iron markers were assessed in both groups. All patients were screened for HFE mutations (C282Y, H63D, S65C). Thirty-six of 61 patients from the study group and all controls had liver biopsy performed with semiquantitative assessment of iron deposits in hepatocytes.

Results: The biochemical markers of iron overload and iron deposits in the liver were detected with a higher frequency (70% and 47% respectively) in patients with liver cirrhosis. There were no differences in the prevalence of all HFE mutations in both groups. In patients with a diagnosis of hepatocellular carcinoma, no significant associations with iron disorders and HFE gene mutations were found.

Conclusions: Iron disorders were detected in patients with liver cirrhosis frequently but without significant association with HFE gene mutations. Only the homozygous C282Y mutation seems to occur more frequently in the selected population of patients with liver cirrhosis. As elevated biochemical iron indices accompanied liver iron deposits more frequently in liver cirrhosis compared to controls with chronic liver disease, there is a need for more extensive studies searching for the possible influence of non-HFE iron homeostasis regulators and their modulation on the course of chronic liver disease and liver cirrhosis.

Citing Articles

Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC.

Wei Y, Ye W, Zhao W Front Physiol. 2018; 9:66.

PMID: 29467672 PMC: 5808349. DOI: 10.3389/fphys.2018.00066.


[Hfeprotein impact on iron metabolism].

Kaczorowska-Hac B, Kaczor J Dev Period Med. 2017; 21(2):85-90.

PMID: 28796976 PMC: 8522971.


Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.

Ye Q, Qian B, Yin W, Wang F, Han T PLoS One. 2016; 11(9):e0163423.

PMID: 27657935 PMC: 5033482. DOI: 10.1371/journal.pone.0163423.


Recent advances in hemochromatosis: a 2015 update : a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia.

Ekanayake D, Roddick C, Powell L Hepatol Int. 2015; 9(2):174-82.

PMID: 25788196 DOI: 10.1007/s12072-015-9608-2.


Evidence for the Influence of the Iron Regulatory MHC Class I Molecule HFE on Tumor Progression in Experimental Models and Clinical Populations.

Weston C, Connor J Transl Oncogenomics. 2014; 6:1-12.

PMID: 25520556 PMC: 4259395. DOI: 10.4137/TOG.S19064.